Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.9800 (2.41%) ($2.8000 - $3.0500) on Wed. Apr. 6, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.81% (three month average) | RSI | 69 | Latest Price | $2.9800(2.41%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.7% a day on average for past five trading days. | Weekly Trend | HTBX advances 3.5% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EWP(69%) GLD(68%) EWI(60%) EDOC(49%) PAVE(49%) | Factors Impacting HTBX price | HTBX will decline at least -2.405% in a week (0% probabilities). TIP(-28%) BWX(-13%) BNDX(-8%) SHY(-6%) IGOV(-0%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.405% (StdDev 4.81%) | Hourly BBV | 0.4 () | Intraday Trend | 2.8% | | | |
|
5 Day Moving Average | $3.02(-1.32%) | 10 Day Moving Average | $3.04(-1.97%) | 20 Day Moving Average | $2.8(6.43%) | To recent high | -5.4% | To recent low | 41.9% | Market Cap | $328m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |